Optimizing Pharmacokinetics In Clinical Development

If you've ever watched a clinical trial stall over dosing uncertainty or seen patients drop out due to overly demanding protocols, pharmacokinetics (PK) may not have been the first place you looked for answers. It should be. Dr. Toni Grant, Director of Pharmacokinetics at Vince Clinical Research, made that case directly at the ASCPT 2025 Annual Meeting in Washington, D.C., and the argument is harder to dismiss than you might expect.

The core idea: PK modeling isn't just a regulatory checkbox or a back-end analysis tool. Applied early and consistently, it can anchor dose selection decisions, flag potential efficacy or safety issues before they become expensive problems, and help you design studies that ask less of participants without sacrificing data quality.

That last point matters more than it used to. Recruitment and retention pressures are real, and study burden is a documented contributor to dropout rates. Optimizing visit schedules and sampling strategies through PK modeling is one way to address that without compromising what you learn.

Access the full presentation to see how Dr. Grant's framework applies to your development program.